Literature DB >> 33370341

Borrelia burgdorferi and Borrelia miyamotoi seroprevalence in California blood donors.

Sharon I Brummitt1, Anne M Kjemtrup2, Danielle J Harvey3, Jeannine M Petersen4, Christopher Sexton4, Adam Replogle4, Andrea E Packham5, Evan M Bloch6, Alan G Barbour7, Peter J Krause8, Valerie Green9, Woutrina A Smith1.   

Abstract

The western blacklegged tick, Ixodes pacificus, an important vector in the western United States of two zoonotic spirochetes: Borrelia burgdorferi (also called Borreliella burgdorferi), causing Lyme disease, and Borrelia miyamotoi, causing a relapsing fever-type illness. Human cases of Lyme disease are well-documented in California, with increased risk in the north coastal areas and western slopes of the Sierra Nevada range. Despite the established presence of B. miyamotoi in the human-biting I. pacificus tick in California, clinical cases with this spirochete have not been well studied. To assess exposure to B. burgdorferi and B. miyamotoi in California, and to address the hypothesis that B. miyamotoi exposure in humans is similar in geographic range to B. burgdorferi, 1,700 blood donor sera from California were tested for antibodies to both pathogens. Sampling was from high endemic and low endemic counties for Lyme disease in California. All sera were screened using the C6 ELISA. All C6 positive and equivocal samples and nine randomly chosen C6 negative samples were further analyzed for B. burgdorferi antibody using IgG western blot and a modified two ELISA test system and for B. miyamotoi antibody using the GlpQ ELISA and B. miyamotoi whole cell sonicate western blot. Of the 1,700 samples tested in series, eight tested positive for antibodies to B. burgdorferi (0.47%, Exact 95% CI: 0.20, 0.93) and two tested positive for antibodies to B. miyamotoi (0.12%, Exact 95% CI: 0.01, 0.42). There was no statistically significant difference in seroprevalence for either pathogen between high and low Lyme disease endemic counties. Our results confirm a low frequency of Lyme disease and an even lower frequency of B. miyamotoi exposure among adult blood donors in California; however, our findings reinforce public health messaging that there is risk of infection by these emerging diseases in the state.

Entities:  

Mesh:

Year:  2020        PMID: 33370341      PMCID: PMC7769429          DOI: 10.1371/journal.pone.0243950

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  42 in total

1.  Healthy donor effect: its magnitude in health research among blood donors.

Authors:  Femke Atsma; Ingrid Veldhuizen; André Verbeek; Wim de Kort; Femmie de Vegt
Journal:  Transfusion       Date:  2011-02-22       Impact factor: 3.157

2.  Seroreactivity to the C6 Peptide in Borrelia miyamotoi Infections Occurring in the Northeastern United States.

Authors:  Phillip J Molloy; Karen E Weeks; Brittany Todd; Gary P Wormser
Journal:  Clin Infect Dis       Date:  2018-04-17       Impact factor: 9.079

3.  Impacts of an introduced forest pathogen on the risk of Lyme disease in California.

Authors:  Andrea Swei; Cheryl J Briggs; Robert S Lane; Richard S Ostfeld
Journal:  Vector Borne Zoonotic Dis       Date:  2012-05-18       Impact factor: 2.133

4.  Detection of a Borrelia miyamotoi sensu lato relapsing-fever group spirochete from Ixodes pacificus in California.

Authors:  Jeomhee Mun; Rebecca J Eisen; Lars Eisen; Robert S Lane
Journal:  J Med Entomol       Date:  2006-01       Impact factor: 2.278

5.  Lyme Borreliosis Serology: Performance of Several Commonly Used Laboratory Diagnostic Tests and a Large Resource Panel of Well-Characterized Patient Samples.

Authors:  Claudia R Molins; Mark J Delorey; Christopher Sexton; Martin E Schriefer
Journal:  J Clin Microbiol       Date:  2016-08-24       Impact factor: 5.948

6.  Evaluation of a serological test for the diagnosis of Borrelia miyamotoi disease in Europe.

Authors:  Setareh Jahfari; Denis S Sarksyan; Nadezda M Kolyasnikova; Joppe W Hovius; Hein Sprong; Alexander E Platonov
Journal:  J Microbiol Methods       Date:  2017-03-01       Impact factor: 2.363

7.  Human Borrelia miyamotoi infection in the United States.

Authors:  Peter J Krause; Sukanya Narasimhan; Gary P Wormser; Lindsay Rollend; Erol Fikrig; Timothy Lepore; Alan Barbour; Durland Fish
Journal:  N Engl J Med       Date:  2013-01-17       Impact factor: 91.245

8.  Serologic evidence for Borrelia hermsii infection in rodents on federally owned recreational areas in California.

Authors:  Curtis L Fritz; Jessica R Payne; Tom G Schwan
Journal:  Vector Borne Zoonotic Dis       Date:  2013-03-14       Impact factor: 2.133

9.  Human Borrelia miyamotoi infection in California: Serodiagnosis is complicated by multiple endemic Borrelia species.

Authors:  Peter J Krause; Madeleine Carroll; Natalia Fedorova; Janna Brancato; Cecilia Dumouchel; Fredua Akosa; Sukanya Narasimhan; Erol Fikrig; Robert S Lane
Journal:  PLoS One       Date:  2018-02-08       Impact factor: 3.240

Review 10.  Current Guidelines, Common Clinical Pitfalls, and Future Directions for Laboratory Diagnosis of Lyme Disease, United States.

Authors:  Andrew Moore; Christina Nelson; Claudia Molins; Paul Mead; Martin Schriefer
Journal:  Emerg Infect Dis       Date:  2016-07       Impact factor: 6.883

View more
  1 in total

1.  Global seroprevalence and sociodemographic characteristics of Borrelia burgdorferi sensu lato in human populations: a systematic review and meta-analysis.

Authors:  Yan Dong; Guozhong Zhou; Wenjing Cao; Xin Xu; Yu Zhang; Zhenhua Ji; Jiaru Yang; Jingjing Chen; Meixiao Liu; Yuxin Fan; Jing Kong; Shiyuan Wen; Bingxue Li; Peng Yue; Aihua Liu; Fukai Bao
Journal:  BMJ Glob Health       Date:  2022-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.